Key clinical point: Higher incidence of uncontrolled blood pressure (BP) was observed in patients with chronic myeloid leukemia (CML) receiving nilotinib vs imatinib or dasatinib, which may be involved in the pro-atherogenic mechanism underlying the development of cardiovascular disease in nilotinib-treated patients.
Major finding: Overall, 47.9% of patients were hypertensive and 32.9% of patients showed uncontrolled BP (at least 130/80 mmHg) on 24-hour ambulatory BP monitoring (ABPM). Patients receiving nilotinib vs dasatinib or imatinib showed a higher incidence of uncontrolled BP in ABPM (45.5% vs 20%; P = .041).
Study details : This observational study assessed clinical BP and 24-hour ambulatory BP in 73 patients with CML receiving active tyrosine kinase inhibitor treatment with either imatinib, nilotinib, or dasatinib.
Disclosures: No source of funding was identified. The authors declared no conflict of interests.
Source: Roa-Chamorro R et al. Sci Rep. 2021 Jul 19. doi: 10.1038/s41598-021-94127-2 .